Apollo is partnering with and taking a minority stake in Sofinnova Partners with plans to commit €1 billion ($1 billion) of managed capital to Sofinnova’s investment funds that concentrate on European life sciences investments.
The new partnership is slated to offer entrepreneurs an expanded range of capital solutions to help bring new therapeutic and biotechnology-based solutions to the market, officials said. The investment capital slated for Sofinnova vehicles includes future strategies the firms may develop together.
For Sofinnova, the deal allows them access to Apollo’s global investment platform that includes $513 billion . . .
Continue Reading
Unlock this article instantly, along with the rest of our premium content and daily, weekly and monthly newsletters. We offer pay-as-you-go monthly subscriptions and discounted annual subscriptions with additional benefits: access to Alternatives Watch Research articles and our Annual Investor Compendium.
